奥洛他定与枸地氯雷他定治疗慢性荨麻疹的临床疗效和安全性对比研究  

Comparative study on clinical efficacy and safety of olotadine and desloratadine in the treatment of chronic urticaria

作　　者：杨惠芳[1] YANG Huifang(Department of Dermatology,the First Afiliated Hospital of Gannan Medical College,Ganzhou,Jiangxi,341000,China)

机构地区：[1]赣南医学院第一附属医院皮肤科,江西赣州341000

出　　处：《当代医学》2022年第13期45-48,共4页Contemporary Medicine

基　　金：赣州市指导性科技计划项目(GZ2019ZSF027)。

摘　　要：目的比较奥洛他定与枸地氯雷他定治疗慢性荨麻疹(CU)的临床疗效和安全性。方法选取2019年7月至2020年6月本院收治的100例CU患者作为研究对象,按照随机数字表法分为研究组和对照组,每组50例。研究组给予奥洛他定治疗,对照组给予枸地氯雷他定治疗,比较两组临床疗效、CU症状积分、血清免疫球蛋白E(IgE)、血清炎症因子水平及不良反应发生率。结果研究组治疗总有效率为98.00%,高于对照组的86.00%,差异有统计学意义(P<0.05)。治疗4周后,研究组风团数量、风团大小、瘙痒程度症状积分均低于对照组,差异有统计学意义(P<0.05)。治疗4周后,研究组IgE、白细胞介素-23(IL-23)、肿瘤坏死因子-α(TNF-α)水平均低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论奥洛他定治疗CU的疗效优于枸地氯雷他定,在降低症状积分、改善血清免疫球蛋白及血清炎症因子水平方面优势突出,但两种药物均具有较高的安全性。Objective To compare the clinical efficacy and safety of olotadine and desloratadine in the treatment of chronic urticaria(CU).Methods A total of 100 CU patients admitted to our hospital from July 2019 to June 2020 were selected as the research subject,and they were ivided into study group and control group according to random number table method,with 50 cases in each group.The study group was given olotadine treatment,and the control group was given desloratadine treatment,the clinical efficacy,CU symptom score,serum immunoglobulin E(IgE),serum inflammatory factor levels and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was 98.00%,which was significantly higher than 86.00% of the control group,and the difference was statistically significant(P<0.05).After 4 weeks of treatment,the number of wind masses,the size of wind masses and the degree of pruritus in the study group were lower than those in the control group,and the difference was statistically significant(P<0.05).After 4 weeks of treatment,the levels of IgE,interleukin-23(IL-23)and tumort necrosis factor-α(TNF-α)in the study group were lower than those in the control group,the differences was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Olotadine has better efficacy than desloratadine in the treatment of CU,and has outstanding advantages in reducing symptom score,improving the levels of serum immunoglobulin and serum inflammatory factor,but the safety of both drugs is higher.

关 键 词：慢性荨麻疹 奥洛他定 枸地氯雷他定 症状积分 血清炎症因子 安全性 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]